5-HT(2A)/(2C) receptor agonists potentiate the discriminative cue of (+)-amphetamine in the rat

Neuropharmacology

Volumn 36, Issue 10, 1997, Pages 1471-1475

  Marona Lewicka, Danuta ^a   Nichols, David E ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

2,5 dimethoxy 4 iodoamphetamine (DOI); 5 HT2 receptor; Amphetamine; Dopamine; Drug discrimination; Lysergic acid diethylamide (LSD)

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; AMPHETAMINE; LYSERGIDE; SEROTONIN 2A AGONIST; SEROTONIN 2C AGONIST; DOPAMINE RECEPTOR STIMULATING AGENT; PSYCHEDELIC AGENT; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN AGONIST; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOPAMINERGIC NERVE CELL; DRUG DISCRIMINATION; DRUG POTENTIATION; INTRAPERITONEAL DRUG ADMINISTRATION; LIMBIC SYSTEM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; ANIMAL BEHAVIOR; DRUG EFFECT; DRUG INTERACTION; FEMALE;

AMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; DOPAMINE AGENTS; DRUG INTERACTIONS; FEMALE; HALLUCINOGENS; LYSERGIC ACID DIETHYLAMIDE; MALE; RATS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS;

EID: 0030608647     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(97)00106-8     Document Type: Article

References (26)

1. Bowers, M. B. (1987) The role of the drugs in production of schizophreniform psychoses and related disorders. In Psychopharmacology: The Third Generation of Progress, ed. H. J. Meltzer, pp. 819-823. Raven Press, New York.
2. Brier M., Su T.-P., Elman I., Adler C., Saunders R., de Bartolomeis A., Carson R., Eckelman W. and Pickar D. (1996) Schizophrenia is associated with enhanced amphetamine-induced dopamine release. Neuroscience Abstracts 22: 266.
3. Dixon A. K. (1968) Evidence of catecholamine mediation of the "aberrant" behavior induced by lysergic acid diethylamide (LSD) in the rat. Experientia 15: 743-747.
4. Druhan J. P., Fibiger H. C. and Phillips A. G. (1990) Amphetamine-like stimulus properties produced by electrical stimulation of reward sites in the ventral tegmental area. Behavioural Brain Research 38: 175-184.
5. Glennon R. A., Young R., Hauck A. E. and McKenney J. D. (1984) Structure-activity studies on amphetamine analogs using drug discrimination methodology. Pharmacology, Biochemistry and Behavior 21: 895-901.
6. Herve D., Pickel V. M., Joh T. H. and Beaudet A. (1987) Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons. Brain Research 435: 71-83.
7. Ho B. T. and Huang J. T. (1975) Role of dopamine in d-amphetamine-induced discriminative responding. Pharmacology, Biochemistry and Behavior 3: 1085-1089.
8. Holohean A. M., White F. J. and Appel J. B. (1982) Dopaminergic and serotonergic mediation of the discriminable effects of ergot alkaloids. European Journal of Pharmacology 81: 595-602.
9. 2 receptor-mediated potentiation of dopamine synthesis and central serotonergic deficits. European Journal of Pharmacology 238: 291-296.
10. Kelly P. H. and Iversen L. L. (1975) LSD as an agonist at mesolimbic dopamine receptors. Psychopharmacologia 45: 221-224.
11. Litchfield J. T. and Wilcoxon F. (1949) A simplified method of evaluating dose-effect experiments. Journal of Pharmacology and Experimental Therapeutics 96: 99-112.
12. 3H]RP 62203 binding in the rat brain. European Journal of Pharmacology 233: 37-45.
13. Marona-Lewicka D. and Nichols D. E. (1994) Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-arninoindan. European Journal of Pharmacology 258: 1-13.
14. Nash J. F. (1990) Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis. Life Sciences 47: 2401-2406.
15. Nielsen E. B. and Japsen S. A. (1985) Antagonism of the amphetamine cue by both classical and atypical antipsychotic drugs. European Journal of Pharmacology 111: 167-176.
16. Nielsen E. B. and Scheel-Kruger J. (1986) Cueing effects of amphetamine and LSD: elicitation by direct microinjection of the drugs into the nucleus accumbens. European Journal of Pharmacology 125: 85-92.
17. Pieri L., Pieri M. and Haefely W. (1974) LSD as an agonist of dopamine receptors in the striatum. Nature 252: 588-589.
18. Roth, B. L. and Meltzer, H. Y. (1995) The role of serotonin in schizophrenia. In Psychopharmacology: The Fourth Generation of Progress, ed. F. E. Bloom and D. J. Kupfer, pp. 1215-1228. Raven Press, New York.
19. Schechter M. D. and Cook P. G. (1975) Dopaminergic mediation of the interoceptive cue produced by L-ampheta-mine in rats. Psychopharmacologia 42: 185-192.
20. 2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxymethamiphetamine by blocking the acute stimulation of dopamine synthesis: reversal by L-DOPA. Journal of Pharmacology and Experimental Therapeutics 256: 230-235.
21. 2 receptors exert a state dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine. European Journal of Pharmacology 223: 65-74.
22. Sorensen S. M., Humphreys T. M., Taylor V. L. and Schmidt C. J. (1992) 5-HT2 receptor antagonists reverse amphetamine-induced slowing of dopaminergic neurons by interfering with stimulated dopamine synthesis. Journal of Pharmacology and Experimental Therapeutics 260: 872-878.
23. 1 dopamine receptors. Psychopharmacology 118: 401-409.
24. West W. B., Van Groll B. J. and Appel J. B. (1995) Stimulus effects of d-amphetamine II: DA, NE and 5-HT mechanisms. Pharmacology, Biochemistry and Behavior 51: 69-76.
25. White F. J. and Appel J. B. (1982) Training dose as a factor in LSD-saline discrimination. Psychopharmacology 76: 20-25.
26. Young R. and Glennon R. A. (1986) Discriminative stimulus properties of amphetamine and related phenalkylamines. Medical Research Reviews 6: 99-108.